Valériane Leroy

Summary Sickle cell disease (SCD) is a life‐threatening disease requiring reliable early diagnosis. We assessed the acceptability and diagnostic performances of two rapid diagnostic tests (RDTs) to identify SCD (HbSS, HbSC, HbS/β‐thalassaemia) or SCD carrier (HbS/HbC) in a pilot SCD newborn screening (NBS) strategy in Mali. All consenting delivering women were offered SCD NBS using cord blood sampling on two RDTs (SickleScan® and HemotypeSC®) compared to the high‐performance liquid chromatography (HPLC) gold standard to detect SCD states. From April 2021 to August 2021, 4333 delivering women were eligible of whom 96.1% were offered NBS: 1.6% refused, 13.8% delivered before consenting and 84.6% consented; 3648 newborns were diagnosed by HPLC; 1.64% had SCD (0.63% HbSS, 0.85% HbSC, 0.16 HbS/β‐plus‐thalassaemia); 21.79% were SCD carrier. To detect accurately SCD, SickleScan® had a sensitivity of 81.67% (95% confidence interval [CI]: 71.88–91.46) and a negative predictive value (NPV) of 99.69% (95% CI: 99.51–99.87); HemotypeSC® had a sensitivity of 78.33% (95% CI: 67.91–88.76) and a NPV of 99.64% (95% CI: 99.44–99.83). To detect SCD carrier: SickleScan® sensitivity was 96.10% (95% CI: 94.75–97.45) and NPV, 98.90% (95% CI: 98.51–99.29); HemotypeSC® sensitivity was 95.22% (95% CI: 93.74–96.70) and NPV, 98.66% (95% CI: 98.24–99.03). Routine SCD NBS was acceptable. Compared with HPLC, both RDTs had reliable diagnostic performances to exclude SCD‐free newborns and to identify SCD carriers to be further confirmed. This strategy could be implemented in large‐scale NBS programmes.